Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, November 1, 2026

Back to today

From X

@calvinblissett 1 click

Calvin Blissett on X

Other than the backlog growing linearly every year and taking that at face value here are some secular trends I found that support growth pertinent to $BUKS: Management repeatedly points to several things in earnings calls: developing additional FAA-approved STCs; getting repeat installations from STCs it has already developed; bringing fabrication in-house rather than outsourcing it; increasing production capacity; selling more kits that customers install themselves; doing larger and more complicated special-mission aircraft; expanding systems-integration work; and growing internationally. During FY2026, BUKS invested approximately $2.7M in developing/producing new products BUKS’s Aerospace segment isn’t primarily an OEM. Its core exposure is modifying King Air, Cessna turboprop, Learjet and increasingly Challenger aircraft for ISR, aerial surveillance, sensors, search-and-rescue and other special missions; installing avionics/electronics; and selling modification kits under FAA STCs. 1. The turbine aircraft fleet BUKS targets is projected to grow ~2% annually for 20 years The FAA’s Aerospace Forecast FY2025–2045 projects the turbine general-aviation fleet to grow 2.1% annually through 2045. In contrast, the piston fleet is expected to shrink slightly. The FAA expects essentially all net growth in the traditional GA fleet to come from turbine aircraft. That’s highly relevant because BUKS specifically says its businesses concentrate on King Air and Cessna turboprops, Learjets and other turbine aircraft. 2. Business-jet deliveries are projected to grow ~3% annually for the next decade Honeywell’s 2025 Global Business Aviation Outlook forecasts: 8,500 new business jets worth $283 billion over the next 10 years, the highest value in the forecast’s 34-year history. It projects deliveries to grow at approximately 3% annually, with 2026 deliveries expected to increase another 5% YoY. 3. Honeywell found that 91% of business-aircraft operators expect to fly the same amount or more, with 28% expecting increased flying. The FAA separately forecasts total general-aviation flight hours to increase 19% from 2023 through 2045, with turbine, rotorcraft and experimental aircraft driving the increase. Higher utilization generally supports demand for upgrades and keeping existing aircraft economically useful. That’s relevant to BUKS because many of its products effectively extend or expand the capabilities of existing airframes rather than requiring operators to buy a new aircraft.
@calvinblissett 1 click

Calvin Blissett on X

$BMBL: Warren Buffett in the salad oil scandal days of American Express used scuttlebutt to determine the strength of the most by going to restaurants. Bumble has a similar level of horrible sentiment today. My tiny brain just realized I am in the epicenter of dating apps (being at a 60k student university). I will be asking every girl for the next few weeks their experiences and perspectives on the different dating apps.
@calvinblissett

Calvin Blissett on X

$IRWD: Citizens raised from 8 to 10, profitable FDA approved biotech, raised guidance (second time in a year) to 450m-475m revenue vs 320m est. Bought VectivBio for 1b. Market cap 682m Q2 2026 earnings: LINZESS Pricing Power Powers a Guidance Raise Ironwood Pharmaceuticals delivered a robust Q2 2026, breaking past conservative Q1 expectations by posting $113M in total revenue (+33% YoY) and raising its full-year guidance across the board. The story here is a massive rebound in LINZESS net pricing. The elimination of inflationary rebates drove commercial margins to 78% (up from 69% a year ago). The company capitalized on this cash flow by paying off $200M in convertible notes with cash on hand, effectively de-risking the balance sheet ahead of heavy R&D investments for the apraglutide STARS-2 trial. Full article with charts - link in bio 🐂 𝐁𝐮𝐥𝐥 𝐂𝐚𝐬𝐞 • 𝐏𝐫𝐢𝐜𝐢𝐧𝐠 𝐏𝐨𝐰𝐞𝐫 𝐑𝐞𝐬𝐭𝐨𝐫𝐞𝐝 — The strategic reset of the LINZESS list price at the start of 2026 is paying massive dividends. Favorable gross-to-net rebate timing and eliminated inflationary rebates are driving net sales and commercial margins higher, resulting in a full-year guidance raise. • 𝐁𝐚𝐥𝐚𝐧𝐜𝐞 𝐒𝐡𝐞𝐞𝐭 𝐃𝐞-𝐫𝐢𝐬𝐤𝐞𝐝 — The $200M cash repayment of 2026 convertible notes removes a major maturity overhang, leaving the company well-positioned to self-fund the critical Phase 3 apraglutide trial while generating strong free cash flow. 📷 𝐁𝐞𝐚𝐫 𝐂𝐚𝐬𝐞 • 𝐕𝐨𝐥𝐮𝐦𝐞 𝐆𝐫𝐨𝐰𝐭𝐡 𝐍𝐨𝐫𝐦𝐚𝐥𝐢𝐳𝐢𝐧𝐠 — Despite the net pricing win, LINZESS prescription demand growth decelerated to 4% YoY in Q2, down from 5% in Q1 and the 11-13% growth rates seen in late 2025. The brand is reaching maturity. • 𝐇𝐞𝐚𝐯𝐲 𝐑𝐞𝐥𝐢𝐚𝐧𝐜𝐞 𝐨𝐧 𝐎𝐧𝐞 𝐀𝐬𝐬𝐞𝐭 — Almost 100% of Ironwood's revenue comes from its share of LINZESS profits. With no clear post-LOE strategy communicated, long-term terminal value remains a risk while the pipeline remains highly concentrated on apraglutide. 📷Bullish. Management is executing flawlessly on their stated goals: maximizing LINZESS cash flow, strengthening the balance sheet, and advancing apraglutide. The guidance raise confirms Q1's strength was not a fluke. 𝐊𝐞𝐲 𝐓𝐡𝐞𝐦𝐞𝐬 📷 𝐋𝐈𝐍𝐙𝐄𝐒𝐒 𝐂𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥 𝐌𝐚𝐫𝐠𝐢𝐧𝐬 𝐄𝐱𝐩𝐚𝐧𝐝𝐢𝐧𝐠 [NEW] Accelerating. LINZESS commercial margin jumped to 78% in Q2 2026 from 69% in Q2 2025. This was driven by a combination of a 14% increase in U. S. net sales (to $282.3M) and a YoY decrease in AbbVie/Ironwood commercial costs and discounts (from $76.9M to $63.0M). The January 2026 list price reduction successfully eliminated significant inflationary rebates, directly benefiting the bottom line. 📷 𝐁𝐚𝐥𝐚𝐧𝐜𝐞 𝐒𝐡𝐞𝐞𝐭 𝐃𝐞𝐥𝐞𝐯𝐞𝐫𝐚𝐠𝐢𝐧𝐠 𝐄𝐱𝐞𝐜𝐮𝐭𝐞𝐝 [NEW] Stable. The company successfully executed its plan to repay the $200M aggregate principal amount of its 1.50% convertible senior notes at maturity in June using cash on hand. While cash balances dropped from $220.5M in Q1 to $79.1M, eliminating this near-term maturity removes a significant financial overhang. The remaining $385M on the revolving credit facility represents manageable leverage against >$310M in projected FY26 Adjusted EBITDA. 📷 𝐋𝐈𝐍𝐙𝐄𝐒𝐒 𝐏𝐫𝐞𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 𝐃𝐞𝐦𝐚𝐧𝐝 𝐃𝐞𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐢𝐧𝐠 [NEW] Decelerating. A specific data point contradicts the purely positive narrative: while revenue and profits are surging due to pricing, the underlying prescription volume growth is slowing. Q2 Rx demand grew 4% YoY (59.8M capsules). This marks a sequential deceleration from 5% in Q1 2026, and is down significantly from the 12-13% growth rates experienced in the second half of 2025. Management raised demand guidance to 'mid-single digits,' but the multi-year volume trend is clearly cooling. 📷 𝐒𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐈𝐧𝐜𝐨𝐦𝐞 𝐓𝐚𝐱 𝐍𝐨𝐧-𝐂𝐚𝐬𝐡 𝐃𝐫𝐚𝐠 Stable. Ironwood recorded $22.4M in income tax expense in Q2 (vs $14.2M in Q2 25). The majority of this is non-cash as the company utilizes net operating losses (NOLs). While it doesn't impact immediate cash flow, it continually depresses GAAP EPS and highlights the complex tax situation of historical R&D-heavy biotech models. 𝐎𝐭𝐡𝐞𝐫 𝐊𝐏𝐈𝐬 𝐀𝐝𝐣𝐮𝐬𝐭𝐞𝐝 𝐄𝐁𝐈𝐓𝐃𝐀: $83.0 million Accelerating. Up 66% YoY from $50.1M in Q2 2025. The company’s focus on expense discipline combined with the rebound in LINZESS net pricing continues to generate massive operating leverage. 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐂𝐚𝐬𝐡 𝐅𝐥𝐨𝐰: $58.3 million Reversing positively. A massive swing from Q2 2025, which saw cash from operations at a negative $15.1 million. This robust cash generation enabled the $200M debt repayment without tapping into further credit facilities. 𝐆𝐮𝐢𝐝𝐚𝐧𝐜𝐞 𝐅𝐘𝟐𝟔 𝐓𝐨𝐭𝐚𝐥 𝐑𝐞𝐯𝐞𝐧𝐮𝐞: $460 - $485 million Accelerating. Raised from the prior estimate of $450 - $475M. At the midpoint ($472.5M), this represents an acceleration over the $290 - $310M baseline seen in 2025, heavily driven by the LINZESS pricing structure changes. 𝐅𝐘𝟐𝟔 𝐀𝐝𝐣𝐮𝐬𝐭𝐞𝐝 𝐄𝐁𝐈𝐓𝐃𝐀: >$310 million Accelerating. Raised from the prior floor of >$300 million. Proves that the incremental revenue gains from LINZESS are dropping almost entirely to the bottom line. 𝐅𝐘𝟐𝟔 🔴le-rate debt versus building cash for business development? 𝐒𝐓𝐀𝐑𝐒-𝟐 𝐄𝐧𝐫𝐨𝐥𝐥𝐦𝐞𝐧𝐭 𝐒𝐩𝐞𝐞𝐝 With STARS-2 actively recruiting, are you seeing any enrollment headwinds due to competing GLP-2 trials in the SBS-IF space, and when should investors expect completion of enrollment? 🔴

Investor Letters

All letters

TSOH Weekly Roundup (10/30/2026)

Markel spent $315 million repurchasing shares in Q3 as Thrive agreed to buy ADT for $7.6 billion and Hasbro cited rising adult toy demand.

BBW $363M
TSOH Investment Research 1 click

OSS Q3 FY12/26 Earnings Analysis

One Stop Systems grew Q3 continuing-operations revenue 36% to $12.6 million, raised FY2026 revenue guidance to $45 million, and used $11.8…

OSS $129M
Cestrian Capital Research 1 click

Namib Minerals: Research Flash

Namib Minerals’ How Mine mill reached 55,000 tonnes per month, 36% above prior capacity, while a proposed $30 million Ecobank facility…

NAMM $43M
Atrium Research - Equity Research 2 clicks

Bimergen Energy: Research Flash

Bimergen Energy filed for a Texas retail-power license to supply data centers directly and gained eligibility for federal contracts through…

BESS $19M
Atrium Research - Equity Research 3 clicks

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $104M
Triple S Special Situations Investing 4 clicks

Moon River Moly: Research Note

Moon River Moly’s updated Davidson PEA lifts after-tax NPV to $1.24 billion as flotation raises tungsten output 350% and cuts molybdenum…

MRIVF $22M
Atrium Research - Equity Research 4 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 69 of 271

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.